Friday 6 November 2026 Export TEVA’s income statement to Excel — free account

Teva Pharmaceutical Industries Ltd.

TEVA Healthcare Drug Manufacturers Specialty & Generic

Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.

Revenue: −1.90%
EPS: −47.2%
Free cash flow: −30.3%
Total debt: −0.43%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

42.46 0.68 +1.63%

Follow TEVA

Alert me

Market cap: $48.7B
P/E: 92.6×
Fwd P/E: 30.7×
Dividend yield: —
F-score: 8/9
Altman Z: 0.79
Beneish M: −2.35
Dividend safety: 52/100

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Teva Pharmaceutical Industries Ltd. 10-Q filed Jul 29, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Jul 29, 2026 · accepted 4:02 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Apr 29, 2026: no material changes, the filing says